<DOC>
	<DOCNO>NCT01146197</DOCNO>
	<brief_summary>Gitelman syndrome rare renal disease kidney unable normally retain salt ( sodium , potassium magnesium ) . Main consequence renal leak salt tendency toward low blood pressure , hypokalemia hypomagnesemia contribute cardiac muscle symptom .</brief_summary>
	<brief_title>Input Use Indometacin Gitelman Syndrome Compared Potassium Sparing Diuretics</brief_title>
	<detailed_description>Patients receive random order 75mg/day indometacin ( Chronoindocid® ) , 10-20 mg/day amiloride 50-150 mg /day eplerenone ( Inspra ® ) . The three 6 weeks-periods treatment follow six week washout period . 3-6 week first period treatment , supplementation potassium magnesium orally give , maintain dose throughout study stop 6 week end third period treatment .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Gitelman Syndrome</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Amiloride</mesh_term>
	<mesh_term>Diuretics , Potassium Sparing</mesh_term>
	<mesh_term>Sodium Channel Blockers</mesh_term>
	<criteria>patient 1860 yr old , sex , genetically proven Gitelman 's syndrome , birth pill control woman . counterindication treatment study Other diuretic NAIS treatment amiloride , spironolactone , indometacin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Hypokalemia</keyword>
	<keyword>Hypomagnesemia</keyword>
	<keyword>Salt loose nephropathy</keyword>
</DOC>